Our passion, your health.

24/10/2016

Fidia Farmaceutici’s collagenase has been granted Orphan Drug

Designation by the US FDA for the treatment of advanced Dupuytren’s disease

Abano Terme, October 18, 2016 - Fidia Farmaceutici announced the obtainment of Orphan Drug Designation by the US Food and Drug Administration, for its Vibrio alginolyticus collagenase, produced and purified in the R&D Unit in Noto (Sicily), for the treatment of advanced Dupuytren’s disease (Dupuytren’s contracture).

Fidia Farmaceutici, world leader in the research and development of hyaluronic acid-based products, is one of the few Italian companies eligible to receive, over the last few years, the Orphan Drug Designation by the FDA, assigned to pharmaceutical agents that have been developed specifically to treat a rare medical condition.

Dupuytren’s contracture is a fibrosing hand disorder that results in slowly progressive thickening and shorting of the palmar fascia and can present with palpable collagen ‘cords’ that limit finger movement and hand function (the fingers bend towards the palm and cannot be fully extended), thereby affecting the patient’s quality of life.

Fidia Farmaceutici is developing an innovative therapeutic solution for Dupuytren’s contracture based on the combination of collagenase and hyaluronic acid: on the one hand, the collagenase enzyme breaks down the collagen fibers in the contracting “cords” caused by excessive deposition; on the other hand, hyaluronic acid protects the surrounding tissues, thereby favouring functional repair and helping the patient regain full hand movement.

The company owns patents on Vibrio alginolitycus collagenase and compositions thereof, containing also hyaluronic acid, for various therapeutic applications, such as Dupuytren’s disease, where this therapy is proposed as a safe, non-surgical option to address an important, unmet need and improve the quality of life for people with this painful hand condition.

Fidia Farmaceutici
Fidia Farmaceutici is an Italian company founded in 1946. It is a leader in R&D and marketing of products based on hyaluronic acid, which have many applications in the biomedical field, in areas such as rheumatology, orthopaedics, surgery, wound care, tissue repair and dermo-aesthetics. Fidia Farmaceutici is part of the Milanese P&R Holding group. The company is well established in Italy, with R&D activities carried out both in Abano (where the company’s headquarter is located) and at the Research Unit in Noto (Sicily, Italy), and 80% revenues generated in international markets. Fidia Farmaceutici’s products are marketed in over 100 countries, through wholly-owned subsidiaries – in USA, Kazakhstan, Germany, Spain, Russia and the Middle East – and a comprehensive network of international partners and distributors. Thanks to its investment in research, it has managed to create a time-honoured legacy of products, with over 600 patents to its name.

Source: Fidia farmaceutici

For more information, contact: Elena Fedeli, Responsabile Comunicazione Fidia Farmaceutici, Tel (+39)-049-8232359, Efedeli@fidiapharma.it

Fidia weltweit

Entdecken Sie auch die internationalen Webseiten von Fidia:

Fidia Farmaceutici s.p.a.
Fidia Pharma USA Inc
Fidia Farmaceutica S.L.U.

Fidia Pharma GmbH

Die Stärke aus über 50 Jahren Erfahrung, Forschung, Entwicklung & Vermarktung von Therapieoptionen mit Hyaluronsäure nutzend, starteten wir ab 2014 in Deutschland die Markteinführung genau dieser innovativen Therapieoptionen für die Arthrosetherapie und das moderne Wundmanagement. Weitere Bereiche werden in den kommenden Jahren folgen.